PetMed Express Q4 Revenue Plunges 16% on Prescription Sales Decline; Rejects Acquisition Bids
PETS sits 36% above its 52-week low of $1.57 on elevated volume (3.0× avg).
Summary
PetMed Express reported a 16% year-over-year Q4 revenue decline to $42.8 million, primarily due to lower prescription sales. While the company's net loss of $0.19 per share was better than analyst expectations, the core business continues to face significant headwinds. Critically, the company also revealed it rejected two unsolicited acquisition offers, signaling a strategic decision to pursue independence. This revenue decline and the rejection of acquisition bids are highly significant for a company with a $45 million market cap.
At the time of this announcement, PETS was trading at $2.13 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $45.6M. The 52-week trading range was $1.57 to $4.32. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.